UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000024091 |
|---|---|
| Receipt number | R000027730 |
| Scientific Title | Phase II study of capecitabine and temozolomide (CAPTEM)in patients with unresectable neuroendocrien tumor |
| Date of disclosure of the study information | 2016/09/17 |
| Last modified on | 2023/03/24 18:46:49 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2016/09/17 10:24:39 | ||
| 2 | Update | 2016/09/17 10:35:12 | Key exclusion criteria |
|
| 3 | Update | 2021/03/05 16:16:58 | Recruitment status Date of IRB Last follow-up date |
|
| 4 | Update | 2022/02/26 10:46:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of primary person or sponsor Institute Institute Organization Organization Organization Category of Funding Organization Organization Organization Address Address Tel |
|
| 5 | Update | 2022/02/26 10:49:38 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
| 6 | Update | 2023/03/24 18:46:49 | Recruitment status |
